Impact of ABCB1 C3435T Polymorphism on Treatment Response of Vitamin K Antagonists: A Systematic Review and Meta-analysis

키워드

참고문헌 (50)

1. Miyasaka Y, "Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence", Circulation, 114(2), pp.119~125 (2006)
2. Go AS, "Prevalence of diagnosed atrial fibrillation in adults : national implications for rhythm management and stroke prevention : the AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA)Study", JAMA, 285(18), pp.2370~2375 (2001)
3. Zhu J, "Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017", Pharmacotherapy, 38(9), pp.907~920 (2018)
4. Holbrook AM, "Systematic overview of warfarin and its drug and food interactions", Arch Intern Med, 165(10), pp.1095~1106 (2005)
5. Nutescu EA, "Warfarin and its interactions with foods, herbs and other dietary supplements", Expert Opin Drug Saf, 5(3), pp.433~451 (2006)
6. Becker ML, "Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol", Eur J Clin Pharmacol, 76(10), pp.1457~1464 (2020)
7. Shendre A, "Influence of age on warfarin dose, anticoagulation control, and risk of hemorrhage", Pharmacotherapy, 38(6), pp.588~596 (2018)
8. Ajmi M, "Influence of genetic and nongenetic factors on acenocoumarol maintenance dose requirement in a Tunisian population", Eur J Clin Pharmacol, 74(6), pp.711~722 (2018)
9. Demirkan K, "Response to warfarin and other oral anticoagulants : effects of disease states", South Med J, 93(5), pp.448~454 (2000)
10. Yanik MV, "Influence of kidney transplant status on warfarin dose, anticoagulation control, and risk of hemorrhage", Pharmacotherapy, 37(11), pp.1366~1373 (2017)
11. Johnson JA, "Clinical Pharmacogenetics Implementation Consortium(CPIC)guideline for pharmacogeneticsguided warfarin dosing : 2017 update", Clin Pharmacol Ther, 102(3), pp.397~404 (2017)
12. Elkhazraji A, "Effect of CYP2C9, VKORC1, CYP4F2, and GGCX gene variants and patient characteristics on acenocoumarol maintenance dose: Proposal for a dosing algorithm for Moroccan patients", Drug Discov Ther, 12(2), pp.68~76 (2018)
13. Li W, "Impact of CYP2C9, VKORC1, ApoE and ABCB1 polymorphisms on stable warfarin dose requirements in elderly Chinese patients", Pharmacogenomics, 21(2), pp.101~110 (2020)
14. Tavares LC, "Association between ABCB1 polymorphism and stable warfarin dose requirements in brazilian patients", Front Pharmacol, 9, pp.542~ (2018)
15. Rojo M, "Functionally significant coumarin-related variant alleles and time to therapeutic range in Chilean cardiovascular patients", Clin Appl Thromb Hemost, 26, pp.1076029620909154~ (2020)
16. Sychev DA, "The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation", Drug Metab Pers Ther, 31(3), pp.173~178 (2016)
17. Ieiri I, "Functional significance of genetic polymorphisms in Pglycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)", Drug Metab Pharmacokinet, 27(1), pp.85~105 (2012)
18. Gschwind L, "Role of P-glycoprotein in the uptake", efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model, 2013, pp.113(4), 259~265
19. Wessler JD, "The P-glycoprotein transport system and cardiovascular drugs", J Am Coll Cardiol, 61(25), pp.2495~2502 (2013)
20. Wolking S, "Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: Update of the literature", Clin Pharmacokinet, 54(7), pp.709~735 (2015)
21. Fung KL, "MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer", Cancer Res, 74(2), pp.598~608 (2014)
22. Kimchi-Sarfaty C, "A "silent" polymorphism in the MDR1 gene changes substrate specificity", Science, 315(5811), pp.525~528 (2007)
23. Wang D, "Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability", Pharmacogenet Genomics, 15(10), pp.693~704 (2005)
24. Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", BMJ, 339, pp.b2535~ (2009)
25. "The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis" (2000)[URL]
26. "Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020)"[URL]
27. Luo D, "Optimally estimating the sample mean from the sample size, median, mid-range, and", or mid-quartile range, 2018, pp.27(6), 1785~1805
28. Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and", or interquartile range, 2014, pp.14, 135~
29. Ferrari M, "Association between ABCG2 and ABCB1 genes and warfarin stability : a case-control study", Thromb Res, 134(6), pp.1359~1362 (2014)
30. Kim Y, "C3435T polymorphism of MDR1 gene with warfarin resistance", Clin Chim Acta, 425, pp.34~36 (2013)
31. Issac MS, "EPHX1 and protein Z gene variants in modulation of warfarin dosage?", Mol Diagn Ther, 18(1), pp.73~83 (2014)
32. Gschwind L, "P-glycoprotein : a clue to vitamin K antagonist stabilization", Pharmacogenomics, 16(2), pp.129~136 (2015)
33. Saraeva RB, "Pharmacogenetics of acenocoumarol: CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5 and ABCB1 gene polymorphisms and dose requirements", J Clin Pharm Ther, 32(6), pp.641~649 (2007)
34. de Oliveira Almeida VC, "Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study", Mol Diagn Ther, 18(6), pp.675~683 (2014)
35. Jiménez-Varo E, "Prediction of stable acenocoumarol dose by a pharmacogenetic algorithm", Pharmacogenet Genomics, 24(10), pp.501~513 (2014)
36. Wadelius M, "Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1(MDR1)and other factors", Pharmacogenomics J, 4(1), pp.40~48 (2004)
37. Campos EIF, "Weekly warfarin maintenance dose according to variations in four genes evaluated in patients assisted at a Brazilian anticoagulation clinic", Res Pract Thrombo Haemost, 2(1), pp.230~231 (2018)
38. Bruhn O, "Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance", Expert Opin Drug Metab Toxicol, 10(10), pp.1337~1354 (2014)
39. Shou W, "Gene-wide characterization of common quantitative trait loci for ABCB1 mRNA expression in normal liver tissues in the Chinese population", PLoS One, 7(9), pp.e46295~ (2012)
40. Nakamura T, "Effect of the mutation(C3435T)at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects", Clin Pharmacol Ther, 71(4), pp.297~303 (2002)
41. Mueller JA, "Warfarin dosing and body mass index", Ann Pharmacother, 48(5), pp.584~588 (2014)
42. Bonde AN, "Effect of reduced renal function on time in therapeutic range among anticoagulated atrial fibrillation patients", J Am Coll Cardiol, 69(6), pp.752~753 (2017)
43. White PJ, "Patient factors that influence warfarin dose response", J Pharm Pract, 23(3), pp.194~204 (2010)
44. Whirl-Carrillo M, "Pharmacogenomics knowledge for personalized medicine", Clin Pharmacol Ther, 92(4), pp.414~417 (2012)
45. Vahedi S, "Global alteration of the drugbinding pocket of human P-glycoprotein(ABCB1)by substitution of fifteen conserved residues reveals a negative correlation between substrate size and transport efficiency", Biochem Pharmacol, 143, pp.53~64 (2017)
46. Silva R, "Modulation of P-glycoprotein efflux pump : induction and activation as a therapeutic strategy", Pharmacol Ther, 149, pp.1~123 (2015)
47. Peng LL, "Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy", Acta Pharmacol Sin, 37(11), pp.1442~1448 (2016)
48. Park MW, "Evaluation of the incremental prognostic value of the combination of CYP2C19 poor metabolizer status and ABCB1 3435 TT polymorphism over conventional risk factors for cardiovascular events after drug-eluting stent implantation in East Asians", Genet Med, 18(8), pp.833~841 (2016)
49. Zhai Y, "Meta-analysis of effects of ABCB1polymorphisms on clopidogrel response among patients with coronary artery disease", Eur J Clin Pharmacol, 73(7), pp.843~854 (2017)
50. Xie Q, "Effect of ABCB1 genotypes on the pharmacokinetics and clinical outcomes of new oral anticoagulants : a systematic review and meta-analysis", Curr Pharm Des, 24(30), pp.3558~3565 (2018)

관련 논문AI추천